Synta Pharmaceuticals (NASDAQ:SNTA) has just announced preliminary results from an investigator-sponsored Phase I clinical trial of its flagship product ganetespib. The small study which was led and designed by researchers at New York University Langone Medical Center and Memorial Sloan Kettering Cancer Center evaluated ganetespib in combination with paclitaxel and trastuzumab in women with HER2+ metastatic breast cancer that was refractory to treatment with other HER2 inhibitors. The study enrolled six heavily pretreated patients who prior to entering the trial, receive a median of 3.5 anti-HER2 including trastuzumab, pertuzumab, and ado-trastuzumab emtansine. The trial was done to see if ganetespib could lead to a full or partial tumor response in addition to extending progression free survival. The results were decent. Of the five patients evaluable for efficacy, partial tumor response was observed in one patient who remains on study, and four patients achieved stable disease ranging in duration from 11 to 29 weeks. Median progression free survival was 19.4 weeks and the proportion of patients achieving objective response or stable disease greater than 24 weeks was 60%. Side effects were minimal.
When I previously covered Synta in depth, I had argued that...READ MORE
No comments:
Post a Comment